Sanofi Bets Big On mRNA Vaccines With Expanded Translate Pact
New Deal Could Be Worth Over $2.3bn
Sanofi and Translate Bio, which hope to advance their mRNA vaccine candidate into a first-in-human clinical trial in the fourth quarter of 2020, have significantly extended their collaboration in that field, with the French giant plonking down a whopping $425m upfront fee.
